

CMS Issues Final Notice on Transitional Coverage for Emerging Technologies

- On August 12, 2024, the Centers for Medicare and Medicaid Services (CMS) issued a Final Notice on Transitional Coverage for Emerging Technologies (Final Notice).
- This notice describes how CMS will use the national coverage determination (NCD) and Coverage with Evidence Development (CED) processes to provide transitional coverage for emerging technologies (TCET), for certain Breakthrough Devices that are Food and Drug Administration (FDA) market authorized.
- The TCET pathway is voluntary and is available immediately, with the first quarterly deadline for manufacturers to nominate a product for the pathway set for October 31.
- The number of products eligible for the pathway is limited to just five (5) per year and is available only to those devices that are:
 - FDA-designated Breakthrough Devices;
 - Determined to be within a Medicare benefit category;
 - Not already the subject of an existing Medicare national coverage determination (NCD); and
 - Not otherwise excluded from coverage through law or regulation.
- Eligible products must treat a life-threatening or irreversibly debilitating condition and otherwise merit breakthrough status, such as by offering significant advantages over existing alternatives.
- This Final Notice is effective August 12, 2024.

More on This Topic:

- [Final Notice](#)

For questions, please reach out to [Vicky Jucelin](#).

AMCP | 675 North Washington Street, Suite 220 | Alexandria,VA,22314

[Manage Preferences](#)

